发明名称 INFLAMMATION INHIBITING COMPOUNDS
摘要 Use of lysine derivatives (I), or their acceptable salts for treatment and/or prevention of inflammatory diseases. Use of lysine derivatives of formula (I), or their acceptable salts, for treatment and/or prevention of inflammatory diseases. X : hydroxy, amino, alkoxy, Pro or Pro-Thr (I) may be N-acylated and/or C-amidated or -esterified. An independent claim is also included for in vitro preparation of cells that can impart tolerance to an antigen (Ag) by treating antigen-presenting cells (APC) with alpha-melanocyte stimulating hormone (aMSH), or its biologically active fragments or derivatives, and with Ag, in either order or simultaneously. [Image] ACTIVITY : Antiinflammatory; Antiallergic; Immunosuppressive; Antifibrotic; Dermatological; Antipsoriatic; Antiasthmatic; Antiulcer. Mice were sensitized to the hapten DNFB, then (after 7 days) the same hapten was applied to the ear, and after a further 24 hr the swelling of the ear was measured. The mean value was 7 (mmX10 -2>), but only 1 when the mice had been injected, intraperitoneally, with an unspecified dose of Lys-Pro-Thr, 2 hr before sensitization. The treated animals did not respond to a second sensitization/challenge, showing that tolerance had been induced. MECHANISM OF ACTION : (I) inhibits activation of the NF-kappaB transcription factor by cytokines or lipopolysaccharide; Reduces expression of costimulatory molecules from dendritic cells and increases production of interleukin-10 from monocytes. (I) may bind to the beta -adrenergic and type 1 interleukin-1 receptors, possibly also to other receptors.
申请公布号 PT2198723(E) 申请公布日期 2013.06.12
申请号 PT20100154643T 申请日期 2002.02.08
申请人 THOMAS LUGER;THOMAS BRZOSKA;STEPHAN GRABBE 发明人 THOMAS LUGER
分类号 A61K31/198;C12N5/06;A23L1/305;A61K8/30;A61K9/06;A61K38/00;A61K38/04;A61K38/05;A61K38/06;A61K39/00;A61P1/00;A61P11/02;A61P11/06;A61P17/00;A61P17/06;A61P29/00;A61P37/02;A61P37/06;A61P37/08;C07K5/068;C07K5/09 主分类号 A61K31/198
代理机构 代理人
主权项
地址